Zealand Pharma wraps up patient enrollment in SBS trial

Denmark’s Zealand Pharma has finished enrolling patients in a phase II trial with candidate glepaglutide for the treatment of short bowel syndrome. The first data are expected later this year.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Dansk epilepsialarm er blevet solgt til USA

Selskabet Ictalcare, der har Coloplast i ejerkredsen og har udviklet en særlig epilepsialarm, har solgt sine aktiver til et amerikansk selskab. Det er konklusionen på en strategisk proces, som har varet i flere år.

Latest Top picks in English

Related articles